ORNBV Orion Oyj Class B

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Liisa Hurme

ORION CORPORATION      MANAGERS’ TRANSACTIONS 29th April 2020 at 13.15 EEST



Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Person subject to the notification requirement
Name:Hurme, Aino Anna Liisa 
Position:Other senior manager
   
Initial Notification 
Reference number:74370029VAHCXDR7B745_20200429112745_10
   
Issuer
Name:Orion Oyj
LEI:74370029VAHCXDR7B745
   
Transaction details
Transaction date:2020-04-29
Venue:NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction:Disposal
 
Instrument:Share
ISIN:FI0009014377
 
Volume:153
Unit price:47,99500 Euro
Volume:60
Unit price:47,99500 Euro
Volume:8
Unit price:47,96000 Euro
Volume:22
Unit price:47,96000 Euro
Volume:23
Unit price:47,96000 Euro
Volume:35
Unit price:47,96000 Euro
Volume:136
Unit price:47,92000 Euro
Volume:200
Unit price:47,95000 Euro
Volume:24
Unit price:47,93000 Euro
Volume:60
Unit price:47,91000 Euro
Volume:71
Unit price:47,88000 Euro
Volume:184
Unit price:47,95000 Euro
Volume:24
Unit price:47,95000 Euro
Volume:2842
Unit price:47,90000 Euro
Volume:740
Unit price:47,90000 Euro
Volume:418
Unit price:47,90000 Euro
Volume:34
Unit price:48,25000 Euro
Volume:35
Unit price:48,25000 Euro
Volume:283
Unit price:48,25000 Euro
Volume:1648
Unit price:48,25000 Euro
Volume:318
Unit price:48,18000 Euro
Volume:200
Unit price:48,12000 Euro
Volume:68
Unit price:48,12000 Euro
Volume:65
Unit price:48,10000 Euro
Volume:22
Unit price:48,10000 Euro
Volume:23
Unit price:48,09000 Euro
Volume:21
Unit price:48,08000 Euro
Volume:21
Unit price:48,05000 Euro
Volume:65
Unit price:48,05000 Euro
Volume:100
Unit price:48,05000 Euro
Volume:100
Unit price:48,05000 Euro
Volume:117
Unit price:48,05000 Euro
Volume:65
Unit price:48,04000 Euro
Volume:22
Unit price:48,04000 Euro
Volume:100
Unit price:48,03000 Euro
Volume:42
Unit price:48,01000 Euro
Volume:160
Unit price:48,09000 Euro
Volume:123
Unit price:48,02000 Euro
Volume:105
Unit price:48,02000 Euro
Volume:200
Unit price:48,12000 Euro
Volume:63
Unit price:48,12000 Euro
Volume:44
Unit price:48,10000 Euro
Volume:180
Unit price:48,10000 Euro
Volume:200
Unit price:48,08000 Euro
Volume:43
Unit price:48,10000 Euro
Volume:60
Unit price:48,06000 Euro
Volume:28
Unit price:48,06000 Euro
Volume:5
Unit price:48,06000 Euro
Volume:100
Unit price:48,06000 Euro
Volume:148
Unit price:48,05000 Euro
Volume:60
Unit price:48,04000 Euro
Volume:100
Unit price:48,04000 Euro
Volume:32
Unit price:48,02000 Euro
Volume:245
Unit price:48,10000 Euro
Volume:755
Unit price:48,10000 Euro
 
Aggregated transactions
Volume:11000
Volume weighted average price:48.03606 Euro

Orion Corporation

Timo LappalainenOlli Huotari
President and CEO   SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

EN
29/04/2020

Underlying

ORNBVOrion Oyj Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion announces agreement with Shilpa Medicare for Recombinant Human A...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST         Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is ...

May 23, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin album...

Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin albumiini -tuotteen oikeuksista Euroopassa ORION OYJ        LEHDISTÖTIEDOTE        23.5.2025 KLO 12.40          Orion ja Shilpa Medicare sopimukseen rekombinantti ihmisseerumin albumiini -tuotteen oikeuksista Euroopassa Orion Oyj ja Shilpa Biocare Private Limited, joka on Shilpa Medicare Limitedin ("Shilpa") kokonaan omistama tytäryhtiö, ovat tehneet sopimuksen rekombinantti ihmisseerumin albumiini -tuotteen kaupallistamisesta Euroopassa. Rekombinantti ihmisseerumin albumiini on keskeinen plasmaproteiini, jota käytetään us...

May 23, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki ORION CORPORATION INVESTOR NEWS 22 MAY 2025 at 10.15 EEST         Orion to host Capital Markets Day today, 22 May 2025, in Helsinki Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media representatives in Helsinki today, 22 May 2025. At the event, members of the Orion Executive Management Board will discuss Orion’s growth strategy, financial objectives, and businesses. Orion will not publish new strategic or financial targets in connection with the event. The presentation material...

May 22, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä

Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä ORION OYJ        LEHDISTÖTIEDOTE        22.5.2025 KLO 10.15         Orion järjestää pääomamarkkinapäivän tänään 22.5.2025 Helsingissä Orion järjestää pääomamarkkinapäivän analyytikoille, institutionaalisille sijoittajille, pankkiireille sekä tiedotusvälineiden edustajille Helsingissä tänään 22.5.2025. Tilaisuudessa Orionin johtoryhmän jäsenet puhuvat Orionin kasvustrategiasta, taloudellisista tavoitteista sekä liiketoiminnoista. Orion ei julkista uusia strategisia tai taloudellisia tavoitteita tilaisuuden yhteydessä. Es...

May 22, 2025 1 EN
 PRESS RELEASE
Free
ORNBV Orion Oyj Class...

Orion’s collaborator, MSD, expands clinical development program for op...

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST                    Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women’s cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of opevesostat for the treatment of breast, endometrial and ovarian cancers has been posted to ClinicalTrials.gov database. The stu...

May 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch